US2013288362A1PendingUtilityA1

Compositions and methods for producing adaptive regulatory t cells

60
Assignee: DARTMOUTH COLLEGEPriority: May 29, 2007Filed: Apr 4, 2013Published: Oct 31, 2013
Est. expiryMay 29, 2027(~0.8 yrs left)· nominal 20-yr term from priority
Inventors:Randolph J. Noelle
A61K 2035/122C12N 2501/385A61P 37/02A61K 40/418A61K 40/42A61K 40/22A61K 40/11A61K 39/001A61K 2239/38A61K 2239/31C12N 5/0637C12N 5/0636
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a method for producing adaptive regulatory T cells from effector T cells by contacting the effector T cells with retinoic acid. Adaptive regulatory T cells produced by this method are Foxp3+, home to the gut, and are refractory to reversion in vivo. As such, such cells find application in the treatment of autoimmune disease and facilitating transplantation tolerance.

Claims

exact text as granted — not AI-modified
1 - 6 . (canceled) 
     
     
         7 : An isolated population of retinoic acid-induced adaptive regulatory T cells produced by a method wherein an isolated effector T cell population is contacted with a retinoic acid in combination with transforming growth factor beta1 (TGFβ1) and interleukin-2 (IL-2), and characterized as a population of adaptive regulatory T cells that are more than 50% CD4+, Foxp3+, α4β7+, CCR9+, and CD103+ cells which are refractory to reversion in vivo.

Join the waitlist — get patent alerts

Track US2013288362A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.